Axsome v. Aurobindo: Sunosi Solriamfetol ANDA Case Consolidated in NJ
Axsome Malta and Axsome Therapeutics filed suit against Aurobindo Pharma in the District of New Jersey asserting four Orange Book patents covering their Sunosi (solriamfetol) wakefulness drug. The standalone action lasted just 34 days before being consolidated into a broader multi-defendant ANDA litigation involving Alkem, Hetero, and Hikma.
Axsome’s Sunosi Patent Campaign: ANDA Multi-Front Strategy in New Jersey
On August 21, 2024, Axsome Malta Ltd. and Axsome Therapeutics, Inc. filed Civil Action No. 2:24-cv-08624 in the District of New Jersey against Aurobindo Pharma Ltd. and Aurobindo Pharma Limited, Inc., asserting infringement of four Orange Book-listed patents — US11986455B2, US11998639B2, US11986454B1, and US12005036B1 — covering solriamfetol, the active ingredient in Axsome’s branded wakefulness-promoting product Sunosi. The suit was triggered by Aurobindo’s filing of an Abbreviated New Drug Application (ANDA) seeking approval for generic solriamfetol oral tablets equivalent to Sunosi at 75 mg and 150 mg base doses.
The case closed on September 24, 2024 — just 34 days after filing — when Axsome and Aurobindo jointly requested consolidation into the Main Action, Civil Action No. 23-20354. That underlying proceeding, originating in September 2023, already encompassed multiple generic challengers including Alkem, Hetero, and Hikma following a wave of consolidation orders in May 2024. Consolidation is a procedural mechanism that merges parallel cases before a single judge to avoid duplicative proceedings; it carries no merits ruling and does not resolve infringement or validity questions.
The 34-day lifespan of this docket is consistent with Axsome’s pattern of filing standalone complaints against each new ANDA filer before promptly consolidating into the Main Action — a common Hatch-Waxman litigation strategy that preserves the 30-month stay trigger while rationalising court resources. The public record does not disclose any licensing discussions, claim construction positions, or substantive defences exchanged in this specific docket. All substantive proceedings are now expected to unfold in the consolidated Main Action before Judge Madeline Cox Arleo.
Filing to Case Consolidated in 34 days
34 days — resolved by consolidation, well under the typical ANDA Hatch-Waxman 30-month stay window
Case consolidated: what the transfer to the Main Action means for both parties
Consolidation terminates this docket without a merits ruling
When the court consolidates related actions, the individual docket is administratively closed and all proceedings — discovery, claim construction, trial — continue under the Main Action case number. No infringement finding, invalidity ruling, or damages award issues from the consolidated case itself. For Hatch-Waxman ANDA suits, consolidation is standard practice when multiple generics challenge the same Orange Book patents, allowing a single Markman hearing and coordinated scheduling.
Procedural — no merits decidedAxsome retains all four patents in active litigation
Consolidation is neutral for Axsome’s substantive position. All four asserted patents — US11986455B2, US11998639B2, US11986454B1, and US12005036B1 — remain in force and are actively litigated in the Main Action. The 30-month stay triggered by this filing continues to block FDA approval of Aurobindo’s ANDA absent a court order or consent. Axsome’s multi-defendant strategy suggests confidence in its Orange Book patent coverage across multiple formulation and method claims.
Patents remain in forceAurobindo now litigates alongside Alkem, Hetero, and Hikma
Consolidation places Aurobindo in the same proceeding as other generic challengers, which can be advantageous — shared invalidity arguments and joint claim construction positions reduce individual litigation costs. However, it also means Aurobindo’s specific ANDA product and patent mapping will be scrutinised alongside competing generics. The consolidated proceeding increases settlement complexity, as any licence or consent judgment for one defendant could affect the others’ positions.
Joined multi-defendant actionSunosi market exclusivity hinges on consolidated NJ proceedings
With at least four active generic challengers now before the same New Jersey court, the outcome of the consolidated Main Action will determine when and whether a lower-cost solriamfetol product reaches the US market. Pharma IP teams monitoring wake-promoting agents should track the Main Action (No. 23-20354) for claim construction rulings and any settlement patterns. A single adverse validity ruling in the consolidated case could open the market to multiple generics simultaneously.
Market entry timing at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Specialty pharma — holder of four Orange Book-listed Sunosi (solriamfetol) patentsSearch in Eureka ↗ |
| Co-Plaintiff | Axsome Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Indian generic pharmaceutical manufacturer and its US subsidiary seeking Sunosi ANDA approvalSearch in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma Limited, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | WILLIAM HARE | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | McNeely, Hare & War LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects a joint request by both parties — not a unilateral court action — indicating that Aurobindo and Axsome agreed this docket was redundant with the Main Action. The verdict language confirms no substantive rulings were issued here. The scope of infringement allegations, validity challenges to the four asserted patents, and ANDA product mapping all remain live issues to be resolved in Civil Action No. 23-20354. The joint nature of the request is procedurally neutral and does not suggest any concession by either party on the merits.
US11986455B2 and three further patents — solriamfetol formulations and methods
The four asserted patents — US11986455B2, US11998639B2, US11986454B1, and US12005036B1 — are listed in the FDA Orange Book for Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The underlying application numbers (US18/295146, US17/929396, US18/340005, US18/491291) suggest a cluster of continuation-style filings in the 2022–2023 window, consistent with a lifecycle management strategy layering formulation and method claims onto an established small-molecule drug.
Solriamfetol occupies a commercially significant niche among scheduled wakefulness agents, with Sunosi competing against modafinil, armodafinil, and sodium oxybate products. The breadth of a four-patent Orange Book cluster raises the barrier for generic entry — each patent must be designed around, invalidated, or licensed separately. For pharma IP strategists, this portfolio structure is a model of post-approval patent layering; for generic entrants, it signals that any solriamfetol ANDA will face a complex, multi-front litigation requiring coordinated invalidity and non-infringement positions across all four patent families.
Should you run an FTO against US11986455B2 and the Sunosi patent cluster?
Any company developing solriamfetol generics, prodrugs, or related dopamine/norepinephrine reuptake inhibitors for narcolepsy or sleep apnea indications should treat all four Orange Book-listed patents as live FTO risks. The active consolidated litigation in New Jersey and the recency of the underlying application filings mean claim scope has not yet been adjudicated. R&D teams formulating wakefulness agents in the phenylalanine-derived stimulant class should assess whether their compositions or dosing methods fall within the claim language of any of the four asserted patents before advancing to IND stage.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the full claim sets of US11986455B2, US11998639B2, US11986454B1, and US12005036B1 simultaneously, flag continuation risks from pending family members, and surface prior art relevant to invalidity arguments being advanced in the consolidated NJ proceeding. Eureka’s litigation monitoring module also tracks claim construction developments in Case No. 23-20354 in real time, so your FTO assessment updates automatically as the case progresses.
Run a freedom-to-operate analysis on US11986455B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases: solriamfetol and CNS wakefulness patents
Cases involving Orange Book patent enforcement for CNS wakefulness drugs in the District of New Jersey, including comparable multi-defendant ANDA consolidation proceedings.
What this case signals for the Hatch-Waxman pharma IP landscape
Axsome’s serial-filing and consolidation approach is a deliberate playbook. Here is what it means for IP strategy.
Serial ANDA filing triggers are a deliberate patent strategy, not reactive litigation
Axsome filed at least five related actions in New Jersey within a 13-month window, each targeting a different generic filer. This pattern suggests a systematic Orange Book listing strategy designed to trigger separate 30-month stays per defendant while consolidating costs into a single proceeding. IP teams at branded pharma companies should model this approach when building out lifecycle management patent portfolios.
Four patents on a single drug product signals robust lifecycle management
Listing four distinct patents in the Orange Book for Sunosi — including application numbers filed as recently as 2023 — suggests Axsome is actively extending its exclusivity window through continuation and formulation patents. Competitors developing solriamfetol generics or related CNS wakefulness agents should conduct thorough FTO analysis against all four US patents and any pending continuations in the same families.
Axsome v Aurobindo — key questions answered
Case No. 2:24-cv-08624 was a Hatch-Waxman patent infringement action filed by Axsome Malta and Axsome Therapeutics against Aurobindo Pharma in the District of New Jersey on August 21, 2024. It was closed on September 24, 2024 — 34 days later — after both parties jointly requested consolidation into the Main Action, Civil Action No. 23-20354, which encompasses multiple generic challengers to Axsome’s Sunosi (solriamfetol) Orange Book patents.
Axsome asserted four Orange Book-listed patents: US11986455B2, US11998639B2, US11986454B1, and US12005036B1. All four relate to Axsome’s Sunosi (solriamfetol) drug product, a wakefulness-promoting agent approved for narcolepsy and obstructive sleep apnea. The patents correspond to application numbers filed between 2022 and 2023, suggesting a continuation-based lifecycle management portfolio.
Consolidation is a procedural step that merges Case No. 2:24-cv-08624 into the Main Action (No. 23-20354) for coordinated discovery, claim construction, and trial. It does not resolve infringement or validity on the merits. Aurobindo’s ANDA approval remains blocked by the Hatch-Waxman 30-month stay triggered by the original complaint, and all substantive questions will now be decided in the consolidated proceeding.
The consolidated Main Action (No. 23-20354) includes Alkem Laboratories, Aurobindo Pharma USA, Hetero USA and Hetero Labs, Hikma Pharmaceuticals USA, and previously Sandoz and Unichem (both since dismissed). Multiple related civil actions were filed between 2023 and 2024 and consolidated by court order. Axsome has pursued a systematic strategy of filing separate complaints against each ANDA filer before consolidating.
Sunosi is a brand-name oral tablet containing solriamfetol, a dopamine and norepinephrine reuptake inhibitor indicated for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea patients. As a commercially significant Schedule IV drug with no direct generic equivalent, it has attracted multiple ANDA filings from generic manufacturers. Axsome’s Orange Book listing of four patents creates a multi-patent enforcement barrier that requires each generic filer to either design around, invalidate, or licence all listed patents before launching.
PatSnap Eureka searches patents and litigation data to answer instantly.